Assessment of Possible Role of Renin Angiotensin Aldosterone System in Obesity: Review Article

Background: There has been a dramatic rise in the prevalence of obesity around the world, and it is now recognized as a major contributor to health problems. Secondary negative health issues, such as high blood pressure, cardiovascular disease, and type 2 diabetes, are more likely to affect those who are overweight and obese. Body fluid regulation and cardiovascular homeostasis are traditionally attributed to the renin-angiotensin-aldosterone system (RAAS), which is a hormone system. Recent studies have revealed the presence of active RAAS in many different tissues. Adipose tissue is one of these tissues where the RAAS has been found to have functional components.
Objective: Assessment of renin angiotensin aldosterone possible role in obesity.
Methods: PubMed, Google Scholar, and Science Direct were used to search for the terms angiotensin, obesity, and renin-angiotensin-aldosterone system. Although they only looked at the most recent or comprehensive study from July 2003 to July 2022, the authors also looked at references from relevant literature. Documents produced in languages other than English have been rendered invalid due to lack of translation-related information. Dissertations, oral presentations, unpublished publications, conference abstracts, and other items that did not deal with significant scientific research were all ignored.
Conclusion: Experiments suggest that the processes that drive adipose tissue development and metabolism in peripheral organs, as well as the effects of angiotensin on appetite and metabolism, contribute to the increased activity of the renin-angiotensin system in obesity. Although renin angiotensin aldosterone system antagonists are typically used to treat high blood pressure and heart failure, there is growing evidence that they may also be useful in managing obesity and other metabolic diseases.